The Cost-Effectiveness of Immunotherapy in Treating Non-Small Cell Lung Cancer: A Review of Previous Analyses and Graphical Model
Immunotherapy is a potent new treatment for non-small cell lung cancer. However, immunotherapy is much more expensive than many treatment alternatives. Previous cost-effectiveness analyses determined that nivolumab would be cost effective if it elicits a response rate greater than 20% (Sullivan et a...
| Main Author: | |
|---|---|
| Format: | Others |
| Published: |
Scholarship @ Claremont
2018
|
| Subjects: | |
| Online Access: | http://scholarship.claremont.edu/cmc_theses/1814 http://scholarship.claremont.edu/cgi/viewcontent.cgi?article=2801&context=cmc_theses |